Fig. 6 | Nature Communications

Fig. 6

From: A 3,2-Hydroxypyridinone-based Decorporation Agent that Removes Uranium from Bones In Vivo

Fig. 6

In vivo decorporation efficiency and in vitro desorption efficiency results. ad Removal efficiency of U(VI) deposited in the kidneys and femurs compared to the control group. For the single-dose group, mice were ip injected (193 μmol kg−1, molar ratio 92:1) or oral administered (644 μmol kg−1, molar ratio 307:1) with ligands after the iv injection of U(VI) (0.5 mg U(VI) kg−1) and then were killed 24 h later. e The urine & feces excretion percentage for the group 5LIO-1-Cm-3,2-HOPO and 5LIO-(Me-3,2-HOPO) treated with single-dose ip injection or oral administration. f Removal efficiency of U(VI) deposited in the kidneys and femurs compared to the control group, for the multiple-dose group. Mice were given the ligand by ip (97 μmol kg−1, molar ratio 46:1) injection at 3 min, 6 h, 24 h, and 48 h, or at 1 h, 7 h, 25 h, and 49 h after the iv injection of U(VI) (0.5 mg U(VI) kg−1) and were killed 72 h later. g Removal efficiency of U(VI) deposited in the kidneys and femurs compared to the control group, for the delayed multiple-dose group. Mice were given the ligand by ip (193 μmol kg−1, molar ratio 92:1) injection at 6 h, 12 h, 30 h, and 54 h (6 h delayed multiple-dose group), or at 12, 18, 36, and 60 h (12 h delayed multiple-dose group), or at 24, 30, 48, and 72 h (24 h delayed multiple-dose group) after the iv injection of U(VI) (0.5 mg U(VI) kg−1) and were killed 7 d later. *p < 0.05, **p < 0.01, ***p < 0.001 vs. U(VI)-treated control, paired-sample T-test for independent-samples, n = 5 mice. Bars indicate SD, n = 5 mice. h U(VI) desorption efficiency from HAP using 5LIO-1-Cm-3,2-HOPO, 5LIO-(Me-3,2-HOPO) or ZnNa3-DTPA. Source data are provided as a Source Data file

Back to article page